Novo Nordisk A/S Sponsored ADR (NVO)
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
Novo Nordisk has had a somewhat rough summer. Two different interactions with regulators didn't go its way.
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
One of Novo Nordisk's medicines could be helpful for treating Alzheimer's disease. A lot of questions need answering before it'll make any new revenue.
Novo Nordisk: Reality Is Starting To Set In
Novo Nordisk A/S investors recently endured a rare bear market after the stock topped out in June 2024. Novo Nordisk faces heightened competitive risks from arch-rival Eli Lilly, as seen in Eli Lilly's recent results. Novo Nordisk is expanding its coverage into new channels. However, pricing challenges could affect its revenue outlook.
Novo Nordisk: How Concerning Is Wegovy's Growth Come-Off?
Novo Nordisk's sharp price drop following its Q2 2024 results is attributed particularly to slowing sales growth of Wegovy, calling for a closer look at the hugely popular treatment's numbers. A combination of factors resulted in the relative growth cool-off, including prices in the US market, limited supply and competition needs to be considered too. Overall, though, there's a still a lot to like about the company that leads the obesity market, with its upgraded sales outlook and strong projected operating margin.
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk NYSE: NVO is the world's second-largest pharmaceutical company, with a market capitalization of $538 billion. The Danish firm's shares have performed well so far in 2024, returning 23%, outperforming its sector.
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
GLP-1 drugs have helped people lose weight, but they can have other positive effects. A recent study found that they could help with Alzheimer's disease.
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Earlier on Wednesday, Denmark's most valuable company, Novo Nordisk A/S NVO, reported second-quarter earnings that missed the analyst consensus.
Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today
Sales of weight-loss drug Wegovy and type 2 diabetes therapy Ozempic both missed expectations. A combination of supply shortages and competition are proving to be unexpected hurdles.
NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
Novo Nordisk (NYSE:NVO) stock is falling on Wednesday after the pharmaceutical company announced results for the second quarter of 2024. A major blow to the company comes from its revenue of $3.8 billion.
